Literature DB >> 29221895

Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016.

Justin R Ortiz1, Julian Hickling2, Rebecca Jones3, Armen Donabedian4, Othmar G Engelhardt5, Jacqueline M Katz6, Shabir A Madhi7, Kathleen M Neuzil8, Guus F Rimmelzwaan9, James Southern10, David J Spiro11, Joachim Hombach12.   

Abstract

In August 2016, the World Health Organization (WHO) convened the "Eighth meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses" to discuss the regulatory requirements and pathways for licensure of next-generation influenza vaccines, and to identify areas where WHO can promote the development of such vaccines. Participants included approximately 120 representatives of academia, the vaccine industry, research and development funders, and regulatory and public health agencies. They reviewed the draft WHO preferred product characteristics (PPCs) of vaccines that could address prioritized unmet public health needs and discussed the challenges facing the development of such vaccines, especially for low- and middle-income countries (LMIC). They defined the data desired by public-health decision makers globally and explored how to support the progression of promising candidates into late-stage clinical trials and for all countries. This report highlights the major discussions of the meeting.
Copyright © 2017 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Influenza; Nextgeneration influenza vaccine; Pandemic influenza vaccine; Seasonal influenza vaccine; Universal influenza vaccine; Vaccine development

Mesh:

Substances:

Year:  2017        PMID: 29221895     DOI: 10.1016/j.vaccine.2017.11.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Ketogenic diet activates protective γδ T cell responses against influenza virus infection.

Authors:  Emily L Goldberg; Ryan D Molony; Eriko Kudo; Sviatoslav Sidorov; Yong Kong; Vishwa Deep Dixit; Akiko Iwasaki
Journal:  Sci Immunol       Date:  2019-11-15

2.  Adeno-associated virus-vectored influenza vaccine elicits neutralizing and Fcγ receptor-activating antibodies.

Authors:  Daniel E Demminger; Lisa Walz; Kristina Dietert; Helen Hoffmann; Oliver Planz; Achim D Gruber; Veronika von Messling; Thorsten Wolff
Journal:  EMBO Mol Med       Date:  2020-03-12       Impact factor: 12.137

3.  Making Universal Influenza Vaccines: Lessons From the 1918 Pandemic.

Authors:  David M Morens; Jeffery K Taubenberger
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

4.  A possible European origin of the Spanish influenza and the first attempts to reduce mortality to combat superinfecting bacteria: an opinion from a virologist and a military historian.

Authors:  John S Oxford; Douglas Gill
Journal:  Hum Vaccin Immunother       Date:  2019-05-23       Impact factor: 3.452

5.  Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model.

Authors:  Wen-Chun Liu; Raffael Nachbagauer; Daniel Stadlbauer; Shirin Strohmeier; Alicia Solórzano; Francesco Berlanda-Scorza; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer; Randy A Albrecht
Journal:  Vaccines (Basel)       Date:  2021-01-11

6.  Readiness for Responding to a Severe Pandemic 100 Years After 1918.

Authors:  Barbara Jester; Timothy Uyeki; Daniel Jernigan
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

Review 7.  The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine.

Authors:  Sophie A Valkenburg; Nancy H L Leung; Maireid B Bull; Li-Meng Yan; Athena P Y Li; Leo L M Poon; Benjamin J Cowling
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

8.  Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.

Authors:  Angus H Forster; Katey Witham; Alexandra C I Depelsenaire; Margaret Veitch; James W Wells; Adam Wheatley; Melinda Pryor; Jason D Lickliter; Barbara Francis; Steve Rockman; Jesse Bodle; Peter Treasure; Julian Hickling; Germain J P Fernando
Journal:  PLoS Med       Date:  2020-03-17       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.